Effectiveness of topical drug therapy for trichomonas colpitis


  • К. Ю. Ісаєва Danylo Halytsky Lviv National Medical University, Ukraine
  • О. В. Беседін Danylo Halytsky Lviv National Medical University, Ukraine




trichomoniasis, acute course, chronic course, vaginal microbiocenosis, оsarbon


A study to evaluate the efficacy of trichomonas colpitis treatment with topical drug osarbon was performed. This drug consists of three main components: osarsol 250 mg, 300 mg boric acid, 300 mg of glucose and solid fat as an excipient.

We observed 60 women of reproductive age who have been diagnosed with trichomonas colpitis based on clinical and laboratory data.

All patients were divided into two statistically significant, identical groups depending on the treatment. Given that trichomoniasis is a multifocal disease, in accordance with all international guidelines for the treatment used a drug with systemic action ornidazole. Osarbon used for the local therapy.

Group I consisted of 30 patients with the trichomonas infection who received ornidazole for systemic effects for 10 days, II group consisted of 30 patients who also received ornidazole with vaginal suppositories osarbon within 10 days. Same times were treated sexual partners, and were given recommendations on the rules of the treatment course and personal care.

Treatment efficacy was assessed by clinical and etiological criteria.

14 days after treatment etiological recovery was observed in 88.2% patients in group I with acute course of disease and in 61.5% patients with chronic course, that the basis for the additional treatment to complete clinical and etiological recovery. Etiological cure in group II patients with acute trichomoniasis was over 100%, with chronic course respectively 85.7%.

Second tests within three months showed etiological recovery among in 86.7% group I patients and among 100% group II patients.

Thus, combination therapy with vaginal suppositories osarbon has high therapeutic effect in treating trichomonas infection and leads to the restoration of the functional vaginal status.

Author Biographies

К. Ю. Ісаєва, Danylo Halytsky Lviv National Medical University

PhD, associate professor at the Obstetrics and Gynecology Department

О. В. Беседін, Danylo Halytsky Lviv National Medical University

PhD, associate professor at the Obstetrics and Gynecology Department


  1. Gryshkevich, A.N., Kulaga, О.K. “Urogenital trichomoniasis in obstetric practice.” Medical News 8 (2008): 33–6.
  2. Kisina, V.I. “Management of patients with urogenital trichomoniasis with evidence-based medicine.” Gynecology 5 (2005): 304–7.
  3. Kokhanevich, E.V., Ganina, K.P., Sumenko, V.V. Colpocervicoscopy. Atlas. Kyiv. Vyshcha Shkola (1997): 49 p.
  4. Reznichenko, G.I., Reznichenko, N.Y., Potebnia, V.Y., et al. “Treatment of trichomoniasis with drug «Meratin» and «Meratin combi».” Women’s doctor 4 (2007): 9–11.
  5. Pankratov, V.V. “The role of the combination of systemic and local treatment for trichomoniasis.” Gynecology, obstetrics and perinatology questions 2 (2003): 85–8.
  6. Chaika, V.K., Rogovaia, O.N., Adamova, G.M., et al. “New approaches to the treatment of trichomoniasis in women.” Women’s doctor 2 (2006): 6–8.
  7. Solskyi, S.Y., Gnatko, O.P., Chubatyi, A.І. “New approaches to the treatment of urogenital trichomoniasis.” Women’s doctor 1 (2006): 17–19.
  8. Kopylov, V.М., Bochkarev, E.G., Govorun, V.М., et al. Urogenital trichomoniasis: actual questions of diagnostics and treatment. Guidelines for physicians. Moscow. Medicine (2001): 21 p.
  9. Ermolenko, D.K., Isakov, V.A., Rybalkin, S.B., et al. Urogenital trichomoniasis. Guidelines for physicians. St. Petersburg. Veliky Novgorod (2007): 96 p.
  10. Mavrov, G.I., Stepanenko, V.І., Chinov, G.P., Nikitenko, I.M. Urogenital trichomoniasis: new approaches to diagnostics and treatment. Methodological recommendations. Кyiv (2004): 22 p.
  11. Carlton, J.M., Hirt, R.P., Silva, J.C. “Draft Genome Sequence of the Sexually Transmitted Pathogen Trichomonas vaginalis.” Science 315 (2007): 207–12.
  12. World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006–2015. Breaking the chain of transmission. WHO Department of Reproductive Health and Research (2007): 61 p.
  13. Grodstein, F., Goldman, M.B., Cramer, D.W. “Relation of tubal infertility to history of sexually transmitted diseases.” Am J Epidemiol 137.5 (1993): 577–84.
  14. Lazenby, G.B., Unal, E.R., Andrews, A.L. “Cost-effectiveness analysis of annual Trichomonas vaginalis screening and treatment in HIV-positive women to prevent HIV transmission.” Sex Transm Dis 41.6 (2014): 353–58.
  15. Mammen-Tobin, A., Wilson, J.D. “Management of metronidazole-resistant Trichomonas vaginalis-a new approach.” Int J STD AIDS 16.7 (2005): 488–90.
  16. Schmid, G., Narcisi, E., Mosure, D., Secor, W.E., Higgins, J. “Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic.” J Reprod Med 46.6 (2001): 545–9.
  17. Silver, B.J., Guy, R.J., Kaldor, J.M. “Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and metaanalysis.” Sex Transm Dis 41.6 (2014): 369–76.
  18. Donders, G.G., Depuydt, C.E., Bogers, J.P., et al. “Association of Trichomonas vaginalis and cytological abnormalities of the cervix in low risk women.” PLoS One 8.12 (2013): e86266. Available from: [http://www.ncbi.nlm.nih. gov/pubmed/24386492], last accessed Yan 25, 2016.



How to Cite

Ісаєва, К. Ю., & Беседін, О. В. (2016). Effectiveness of topical drug therapy for trichomonas colpitis. REPRODUCTIVE ENDOCRINOLOGY, (27), 101–105. https://doi.org/10.18370/2309-4117.2016.27.101-105



Inflammatory diseases